Showing results (2201-2210 of 2,317) with videos related to
Sort By:
Pageof 232
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.Cancer Cell|March 6, 2026
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trialJianchun Duan, Yuping Sun, Qiming Wang, et al.Development (Cambridge, England)|June 10, 2011
The GUDMAP database--an online resource for genitourinary researchSimon D Harding, Chris Armit, Jane Armstrong, et al.Bioorganic & Medicinal Chemistry Letters|January 8, 2011
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemiaSampath-Kumar Anandan, Heather Kay Webb, Dawn Chen, et al.The New England Journal of Medicine|September 13, 2024
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung CancerYing Cheng, David R Spigel, Byoung Chul Cho, et al.The New England Journal of Medicine|November 21, 2017
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerJean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, et al.The Lancet. Oncology|May 14, 2023
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialPin Zhang, Qingyuan Zhang, Zhongsheng Tong, et al.Nucleic Acids Research|November 13, 2009
Improvements to services at the European Nucleotide ArchiveRasko Leinonen, Ruth Akhtar, Ewan Birney, et al.Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.Pageof 232